Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
83%
Ph phase_3
1
17%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Completed1
Not yet recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (83.3%)
Phase 31 (16.7%)

Trials by Status

completed117%
not_yet_recruiting117%
unknown117%
recruiting233%
withdrawn117%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_2

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

NCT07295132
recruitingphase_2

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

NCT07171528
completedphase_2

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675
recruitingphase_2

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

NCT05704621
withdrawnphase_2

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

NCT04795596
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07295132Phase 2

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Not Yet Recruiting
NCT07171528Phase 2

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

Recruiting
NCT01767675Phase 2

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
NCT05704621Phase 2

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Recruiting
NCT04795596Phase 2

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

Withdrawn
NCT01611766Phase 3

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

Unknown

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6